Johnson & Johnson is to terminate its studies investigating Genmab’s CD38-targeting, human IgG1κ monoclonal antibody Darzalex (daratumumab) in combination with Roche’s PD-L1 inhibitor Tecentriq (atezolizumab) in patients with previously treated non-small cell lung cancer.
Original Article: J&J terminates PD-(L)1 combo studies of cancer therapy Darzalex